(Q36491838)

14 August 2017

1 reference

title

Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain (English)

1 reference

14 August 2017

0 references

Caroline Dive

4

0 references

Malcolm Ranson

series ordinal

3

object named as

Malcolm Ranson

1 reference

14 August 2017

Kathryn Taylor

1

1 reference

14 August 2017

Dimitra Micha

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Expert Opinion on Investigational Drugs

14 August 2017

published in

1 reference

14 August 2017

volume

15

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

669-690

1 reference

Mechanisms and Functions of Cell Death

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Programmed cell death in animal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Drug-target interactions: only the first step in the commitment to a programmed cell death?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Apoptosis: a link between cancer genetics and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Human ICE/CED-3 protease nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Many cuts to ruin: a comprehensive update of caspase substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Lysosomes and autophagy in cell death control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

BID: a novel BH3 domain-only death agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

BH3-Only proteins-essential initiators of apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The role of Bcl-2 family members in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Apoptosis-based therapies for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Antisense therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Identification of chelerythrine as an inhibitor of BclXL function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Antiviral drug discovery strategy using combinatorial libraries of structurally constrained peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

RETRACTED: Inactivation of MAP kinase signalling in Myc transformed cells and rescue by LiCl inhibition of GSK3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Bcl-XL Mutations Suppress Cellular Sensitivity to Antimycin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Molecular mechanisms of caspase regulation during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Understanding IAP function and regulation: a view from Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Caspase-3 expression is reduced, in the absence of cleavage, in terminally differentiated normal oral epithelium but is increased in oral squamous cell carcinomas and correlates with tumour stage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

An exegesis of IAPs: salvation and surprises from BIR motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Survivin as a target for new anticancer interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Targeted therapy by disabling crossroad signaling networks: the survivin paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

A p34(cdc2) survival checkpoint in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Pathways of apoptotic and non-apoptotic death in tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Structural basis of IAP recognition by Smac/DIABLO

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Identification of XAF1 as an antagonist of XIAP anti-Caspase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Apoptosis by death factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Death to the bad guys: targeting cancer via Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

TRAIL and its receptors as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The receptor for the cytotoxic ligand TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

ErbB receptors: directing key signaling networks throughout life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

CI-1033, a pan-erbB tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

PI3K-Akt pathway: its functions and alterations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The protein kinase B/Akt signalling pathway in human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The Akt pathway: molecular targets for anti-cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Drug discovery strategies: technologies to accelerate translation from target to drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Targeting the molecular target of rapamycin (mTOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Cancer. p53, guardian of the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Live or let die: the cell's response to p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

p53 has a direct apoptogenic role at the mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

p53 Activation by small molecules: application in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The p53-mdm-2 autoregulatory feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Inflammation-associated cancer: NF-kappaB is the lynchpin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

NF-kappaB at the crossroads of life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

NF-kappaB in cancer--a friend turned foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Structure-activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: an inhibitor of AP-1 and NF-kappaB mediated gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Novel therapeutic approaches for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Proteasome: an emerging target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Genetic control of programmed cell death in the nematode C. elegans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Bim: a novel member of the Bcl-2 family that promotes apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Mechanism of XIAP-mediated inhibition of caspase-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

Structural basis for the inhibition of caspase-3 by XIAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.669

10.1517/13543784.15.6.669

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference